{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T11:07:38Z","timestamp":1710500858359},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1097\/ftd.0b013e3182a8f0c8","type":"journal-article","created":{"date-parts":[[2013,11,14]],"date-time":"2013-11-14T08:52:08Z","timestamp":1384419128000},"page":"261-263","source":"Crossref","is-referenced-by-count":7,"title":["Dapsone and Body Mass Index in Subjects With Multibacillary Leprosy"],"prefix":"10.1097","volume":"36","author":[{"given":"Fernanda M. L.","family":"Moura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa M.","family":"Dias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliete C.","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"La\u00e9lia M. B. F.","family":"Brasil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle V. D.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose L. F.","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-19-20210129","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1590\/S0074-02762012000900002","article-title":"Leprosy frequency in the world, 1999-2010.","volume":"107","author":"Penna","year":"2012","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"R3-19-20210129","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.det.2010.03.014","article-title":"Innovative use of dapsone.","volume":"28","author":"Wozel","year":"2010","journal-title":"Dermatol Clin"},{"key":"R4-19-20210129","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1067\/mjd.2001.114733","article-title":"Dapsone and sulphones in dermatology: overview and update.","volume":"45","author":"Zhu","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"R6-19-20210129","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1097\/00002030-199011000-00015","article-title":". Low-dose dapsone prophylaxis of Pneumocystis carinii pneumonia in AIDS and AIDS-related complex.","volume":"4","author":"Kemper","year":"1990","journal-title":"AIDS"},{"key":"R7-19-20210129","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2165\/00003088-198611040-00003","article-title":"Clinical pharmacokinetics of dapsone.","volume":"11","author":"Zuidema","year":"1986","journal-title":"Clin Pharmacokinet"},{"key":"R8-19-20210129","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2133.1993.tb00476.x","article-title":"Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance.","volume":"129","author":"Coleman","year":"1993","journal-title":"Br J Dermatol"},{"key":"R9-19-20210129","doi-asserted-by":"crossref","first-page":"17","DOI":"10.47276\/lr.82.1.17","article-title":". Adverse effects of multi-drug therapy in leprosy, a two years experience (2006-2008) in tertiary health care centre in the tribal region of Chhattisgarh State (Bastar, Jagdalpur).","volume":"82","author":"Singh","year":"2011","journal-title":"Lepr Rev"},{"key":"R10-19-20210129","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003088-200039030-00004","article-title":"Effects of obesity on pharmacokinetics implications for drug therapy.","volume":"39","author":"Cheymol","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"R11-19-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/epirev\/mxm012","article-title":"The global epidemic of obesity: an overview.","volume":"29","author":"Caballero","year":"2007","journal-title":"Epidemiol Rev"},{"key":"R12-19-20210129","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1086\/514505","article-title":"Antimicrobial dosing in obese patients.","volume":"25","author":"Wurtz","year":"1997","journal-title":"Clin Infect Dis"},{"key":"R13-19-20210129","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2165\/00003088-199325020-00003","article-title":"Clinical pharmacokinetics of drugs in obesity. An update.","volume":"25","author":"Cheymol","year":"1993","journal-title":"Clin Pharmacokinet"},{"key":"R14-19-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/js980173a","article-title":"Pharmacokinetic considerations in obesity.","volume":"88","author":"Blouin","year":"1999","journal-title":"J Pharm Sci"},{"key":"R15-19-20210129","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/11599410-000000000-00000","article-title":". Impact of obesity on drug metabolism and elimination in adults and children.","volume":"51","author":"Brill","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"R16-19-20210129","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/bmc.132","article-title":"High-performance liquid chromatographic method with ultraviolet detection for the determination of dapsone and its hydroxylated metabolite in human plasma.","volume":"16","author":"Kwadijk","year":"2002","journal-title":"Biomed Chromatogr"},{"key":"R18-19-20210129","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1177\/106002808301700704","article-title":". Procainamide disposition in obesity.","volume":"17","author":"Christoff","year":"1983","journal-title":"Drug Intell Clin Pharm"},{"key":"R19-19-20210129","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1365-2125.2011.03959.x","article-title":"Altered xanthine oxidase and N-acetyltransferase activity in obese children.","volume":"72","author":"Chiney","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"R20-19-20210129","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/11318100-000000000-00000","article-title":"Effect of obesity on the pharmacokinetics of drugs in humans.","volume":"49","author":"Hanley","year":"2010","journal-title":"Clin Pharmacokinet"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e3182a8f0c8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:41:29Z","timestamp":1620952889000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201404000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3182a8f0c8","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}